Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD1 Checkpoint Blockade in Neuroblastoma

Researchers proved that anlotinib facilitated tumor vessel normalization at least partially through CD4+ T cells, reprogrammed the immunosuppressive tumor microenvironment (TME) into an immunostimulatory TME, significantly inhibited tumor growth and effectively prevented systemic immunosuppression.